Viewing nowCombinationHabika Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
White Life Science Co., Ltd.

MFDS item code 201404727 · Approved 2014.10.15 · Insurance code 625200900
Treatment of essential hypertension not controlled with monotherapy
This medication is indicated for patients with essential hypertension whose blood pressure is not adequately controlled with amlodipine or olmesartan medoxomil monotherapy. In other words, it is used to effectively lower blood pressure in the treatment of essential hypertension.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 mg or olmesartan medoxomil 20 mg. - 10/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not be administered this medicine under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Pediatric patients under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. People with allergies to the ingredients in this medication or similar drugs, pregnant women, breastfeeding women, patients with severe liver or kidney impairment, and those with certain heart conditions should not use this medication. Careful observation is necessary when administering this medication to patients who are volume or salt depleted, as blood pressure may drop too low upon initial administration. Due to its vasodilatory effects, there may be an occasional occurrence of severe hypotension, so special caution is needed for patients with heart valve disease. Patients with heart failure or coronary artery disease must use this medication with caution and follow medical instructions for administration. Patients with impaired kidney function should have regular check-ups as this medication may affect kidney function. Patients with reduced liver function may require dose adjustments and careful monitoring as the metabolism of this medication may slow. During treatment, side effects such as dizziness, headache, hypotension, cough, dyspepsia, and skin rash may occur, and patients should inform their healthcare provider of any adverse symptoms. In particular, since potassium levels may increase in the blood, patients at risk of hyperkalemia should undergo regular blood tests. This medication may interact with other antihypertensive drugs or specific medications, so patients must inform their healthcare provider of any medications they are taking. Taking this medication during pregnancy poses a serious risk to fetal health, so individuals planning to become pregnant or who are pregnant should consult a physician. Breastfeeding women are advised to discontinue either breastfeeding or taking this medication since it can be transmitted to breast milk and may affect the baby. The use of this medication is not recommended for children under 18 years of age as its safety and efficacy in this population have not been established. Elderly patients may have reduced kidney and liver function, so careful observation and adjustment of the dose are necessary, along with monitoring for side effects. In cases of overdose, hypotension and decreased cardiac function may occur, necessitating immediate medical attention.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to avoid exposure to air or moisture. It is best to store it at room temperature between 1 and 30 degrees Celsius.
Pale yellow, round film-coated tablet
28 tablets (14 tablets/PTP X 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
White Life Science Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.